Source Gangtise Investment Research

analysts saidjackpotwheelSince the outbreak of swine fever in Africa, non-plague vaccine research and development trials involving scientific research institutions such as the Chinese Academy of Sciences and Zhejiang Hailong have been carried outjackpotwheelIn 4 to 5 years, there is a high possibility that non-plague vaccines will make significant progress in 2024, and clinical trial results may be available before the end of June. If non-plague vaccines can be implemented in 2024, biological shares, Zhongmu shares and other targets are likely to benefit. The revenue increase of each company will reach 1 to 2 billion yuan, and the profit increase will be more than 500 million yuan.